Olema Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, particularly breast cancer. Its lead product candidate, palazestrant (OP-1250), is an oral therapy that acts as both a complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), designed for patients with recurrent, locally advanced, or metastatic estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Palazestrant is currently in the pivotal Phase 3 OPERA-01 trial as a monotherapy in second- and third-line settings, and in Phase 1/2 trials in combination with CDK4/6 inhibitors like palbociclib and ribociclib, as well as other agents such as PI3Ka inhibitor alpelisib and mTOR inhibitor everolimus. The company is also advancing OP-3136, an orally available small molecule that selectively inhibits KAT6, in Phase 1 trials for ER+/HER2- metastatic breast cancer and other solid tumors. Olema Pharmaceuticals Inc. operates in the oncology sector, addressing unmet needs in endocrine-driven cancers through innovative small molecule approaches. Founded in 2006 and headquartered in San Francisco, California, it emphasizes precision medicines to improve treatment outcomes in high-incidence markets.